Zevra Therapeutics, Inc. (ZVRA)
8.40
-0.08
(-0.94%)
USD |
NASDAQ |
Feb 12, 16:00
8.42
+0.02
(+0.24%)
Pre-Market: 20:00
Zevra Therapeutics Cash from Investing (Quarterly) : -4.576M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| XOMA Royalty Corp. | 58.21M |
| Verastem, Inc. | -8.279M |
| ADMA Biologics, Inc. | -14.37M |
| ACADIA Pharmaceuticals, Inc. | -79.35M |
| Alnylam Pharmaceuticals, Inc. | 501.11M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 4.709M |
| Cash from Financing (Quarterly) | 6.53M |
| Free Cash Flow | -24.23M |
| Free Cash Flow Per Share (Quarterly) | 0.0743 |
| Free Cash Flow to Equity (Quarterly) | 3.714M |
| Free Cash Flow to Firm (Quarterly) | 5.297M |
| Free Cash Flow Yield | -5.28% |